For the current 2024-2025 RSV season, Beyfortus® is publicly funded for infants and children who are residents of Ontario and meet any of the following criteria:

• Born in 2024 prior to the RSV season

• Born during the 2024-2025 RSV season

• Children up to 24 months of age who remain vulnerable from severe RSV disease through their second RSV season with specific chronic medical conditions

Pregnant adults can choose to have the RSV vaccination ABRYSVO® in their third trimester, in which case Beyfortus® is not necessary for the protection of their infant. NACI recommends Beyfortus® be given to infants over ABRYSVO® in pregnant individuals.

At NHH, infants are eligible to receive Beyfortus® prior to discharge from the hospital. Expecting parents and new families can also speak with their primary-care physician to learn more about Beyfortus®, or contact the Haliburton Kawartha Pine Ridge District Health Unit at 1-866-888-4577 ext. 1507.